INSMED Inc — Capital/Financing Update 2017

Sep 11, 2017

8-K 1 a17-21316_38k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): September 11, 2017

INSMED INCORPORATED

(Exact name of registrant as specified in its charter)

Virginia	000-30739	54-1972729
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

10 Finderne Avenue, Building 10 Bridgewater, New Jersey	08807
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: ( 908) 977-9900

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

SEQ.=1,FOLIO='',FILE='C:\JMS\105733\17-21316-3\task8569244\21316-3-ba.htm',USER='105733',CD='Sep 9 11:01 2017'

Item 7.01 — Regulation FD Disclosure.

On September 11, 2017, Insmed Incorporated (the “Company”) issued a press release announcing the closing of the public offering of 14,123,150 shares of the Company’s common stock, par value $0.01 per share, at a public offering price of $28.50 per share. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 — Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release issued by Insmed Incorporated on September 11, 2017.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\105733\17-21316-3\task8569244\21316-3-ba.htm',USER='105733',CD='Sep 9 11:01 2017'

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release issued by Insmed Incorporated on September 11, 2017.

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\105733\17-21316-3\task8569244\21316-3-ba.htm',USER='105733',CD='Sep 9 11:01 2017'

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 11, 2017
By:	/s/ Christine Pellizzari
Name:	Christine Pellizzari
Title:	General Counsel and Corporate Secretary

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\105733\17-21316-3\task8569244\21316-3-ba.htm',USER='105733',CD='Sep 9 11:01 2017'